Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tuvusertib + PLX038 in Advanced Solid Tumors
NCT06337630Phase 1Terminated
- Sponsor
- Institut Curie
- Start
- Jan 2025
- Primary completion
- Nov 2025
- Modality
- Polymer-based Nanoparticles, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tuvusertib and PLX038 in solid tumor and triple-negative breast cancer (TNBC), sponsored by Institut Curie. Primary endpoints: Dose Limiting Toxicities at 21 days, Best tumor response at 6 months and 2 more. Started Jan 2025; status: terminated.
02
Drugs
tuvusertibPLX038
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06337630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337630.